Xynomic Pharmaceuticals (XYNO) Stock Price, News & Analysis

Company Overview

Xynomic Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery, development and commercialization of small‐molecule therapies for oncology. Headquartered in Nanjing, China, the company applies an integrated R&D platform encompassing target identification, medicinal chemistry and preclinical modeling to advance its pipeline of novel anti‐cancer candidates. Xynomic’s programs seek to address areas of high unmet need in solid tumors and hematologic malignancies by targeting key signaling pathways that drive tumor growth and survival.

The company’s pipeline comprises multiple proprietary drug candidates at various stages of development, including kinase inhibitors directed against CDK, BRAF and Aurora targets, as well as agents aimed at epigenetic modulation. Several of these compounds have entered early‐ to mid‐stage clinical trials both in China and internationally. Xynomic’s in‐house capabilities span discovery through to clinical proof‐of‐concept, and the company has secured partnerships with regional regulatory bodies to facilitate parallel filing strategies across major markets.

With R&D facilities in China and an affiliate office in the United States, Xynomic serves a global patient population by conducting multi‐center trials in Asia, North America and Europe. The company’s collaborative model includes licensing agreements and strategic alliances with academic institutions, contract research organizations and other biopharma partners. This network supports Xynomic’s goal of accelerating the translation of laboratory findings into safe and effective therapies for patients worldwide.

Key Stats

• Today's Range: $2.22 to $2.22
• 50-Day Range: $2.22 to $2.22
• 52-Week Range: $0.20 to $3.84
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XYNO Stock Analysis - Frequently Asked Questions

How have XYNO shares performed this year?

Xynomic Pharmaceuticals' stock was trading at $2.22 at the beginning of 2025. Since then, XYNO stock has increased by 0.0% and is now trading at $2.22.

How do I buy shares of Xynomic Pharmaceuticals?

Shares of XYNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:XYNO
• CIK: N/A
• Web: xynomicpharma.com
• Phone: 86 21 5418 0212
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A